Self-amplifying mRNA influenza virus vaccine A(H5N1) - Seqirus
Alternative Names: A(H5N1) - Seqirus; sa-mRNA vaccineLatest Information Update: 19 Oct 2023
At a glance
- Originator Seqirus
- Class Influenza A virus H5N1 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Influenza A virus H5N1 subtype
Most Recent Events
- 05 Oct 2023 Phase-I clinical trials in Influenza A virus H5N1 subtype (Prevention) in Australia (unspecified route) (NCT06028347)
- 11 Sep 2023 Seqirus plans a phase I trial in Influenza virus infections (Prevention) in September 2023 (NCT06028347)
- 01 Nov 2022 Arcturus enters into a collaboration with Seqirus to develop and commercialize self-amplifying mRNA vaccines